VERV vs. MOR, TWST, VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, ARWR, and HCM
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Verve Therapeutics vs.
MorphoSys (NASDAQ:MOR) and Verve Therapeutics (NASDAQ:VERV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
MorphoSys presently has a consensus price target of $18.25, indicating a potential downside of 3.74%. Verve Therapeutics has a consensus price target of $25.75, indicating a potential upside of 253.71%. Given Verve Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than MorphoSys.
MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
18.4% of MorphoSys shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Verve Therapeutics had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Verve Therapeutics and 0 mentions for MorphoSys. Verve Therapeutics' average media sentiment score of 0.20 beat MorphoSys' score of 0.00 indicating that Verve Therapeutics is being referred to more favorably in the news media.
MorphoSys has a net margin of -226.79% compared to Verve Therapeutics' net margin of -807.65%. Verve Therapeutics' return on equity of -35.23% beat MorphoSys' return on equity.
MorphoSys and Verve Therapeutics both received 25 outperform votes by MarketBeat users. However, 54.35% of users gave Verve Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
Verve Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Verve Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VERV) was last updated on 2/22/2025 by MarketBeat.com Staff
